Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration
Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration
复制标题
DOI：
10.1038/eye.2009.271
复制
发表时间：
2010-06-01
期刊：
影响因子：
3.9
通讯作者：
Downey, L.
中科院分区：
文献类型：
--
作者：
McKibbin, M.;Papastefanou, V.;Downey, L.
目的：回顾性研究玻璃体内单抗治疗对老年性黄斑变性（ARMD）继发脉络膜新生血管（CNV）患者中央凹下出血的功能影响。患者与方法12例患者12眼，按照目前的做法，采用玻璃体内注射雷尼单抗（0.5 mg / 0.05 ml）治疗。随访安排为每月一次。11例患者随访6个月，7例随访12个月。分析出血持续时间、病灶大小、基线ETDRS信评分及随访情况。结果视网膜下出血完全清除的平均时间为4.7个月（范围3 ~ 7个月）。6个月后，11只眼中有7只视力稳定或改善，ETDRS字母评分平均变化为+7.6个字母（P < 0.05）。12个月后，7只眼中有5只视力稳定或改善，ETDRS评分平均变化为+7.3个字母（P < 0.05）。随访12个月的7例患者，平均注射6次。随访期间，2例患者视力下降415个ETDRS字母。没有其他局部或全身副作用的报道。结论玻璃体内单抗治疗可能是治疗ARMD继发性CNV中央凹下出血的有效方法。眼科杂志（2010）24,994-998；doi: 10.1038 / eye.2009.271;2009年11月13日在线发布
Purpose In a retrospective review, the functional effects of intra-vitreal ranibizumab monotherapy in patients with sub-foveal haemorrhage secondary to choroidal neovascularisation (CNV) in age-related macular degeneration (ARMD) are reported.Patients and methods Twelve eyes of 12 patients were treated with intra-vitreal ranibizumab (0.5 mg in 0.05 ml) in accordance with current practice. Follow-up was arranged at monthly intervals. Eleven patients completed 6 months and seven completed 12 months of follow-up. Duration of haemorrhage, lesion size, ETDRS letter score at baseline, and follow-up were analysed.Results The mean time for complete clearance of sub-retinal haemorrhage was 4.7 months (range 3-7 months). After 6 months, visual acuity was stable or improved in 7 of 11 eyes and the mean change in ETDRS letter score was +7.6 letters (P>0.05). After 12 months, visual acuity was stable or improved in five of seven eyes and the mean change in ETDRS letter score was +7.3 letters (P>0.05). For the seven cases with 12 months of follow-up, a mean of six injections were given. Two patients had a decrease in acuity of 415 ETDRS letters during follow-up. No other local or systemic side-effects were reported.Conclusions Intra-vitreal ranibizumab monotherapy may be an effective treatment for subfoveal haemorrhage secondary to CNV in ARMD. Eye (2010) 24, 994-998; doi: 10.1038/eye.2009.271; published online 13 November 2009